274 related articles for article (PubMed ID: 33169495)
1. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome.
Takemoto M; Kubota Y; Taniguchi T; Motegi SI; Taniguchi A; Nakagami H; Maezawa Y; Koshizaka M; Kato H; Tsukamoto K; Mori S; Kuzuya M; Yokote K
Geriatr Gerontol Int; 2021 Feb; 21(2):142-145. PubMed ID: 33169495
[TBL] [Abstract][Full Text] [Related]
2. Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome.
Kuzuya M; Takemoto M; Kubota Y; Taniguchi T; Motegi SI; Taniguchi A; Nakagami H; Maezawa Y; Koshizaka M; Kato H; Mori S; Tsukamoto K; Yokote K
Geriatr Gerontol Int; 2021 Feb; 21(2):139-141. PubMed ID: 33169468
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
5. Add-on therapies to metformin for type 2 diabetes.
Shomali M
Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
9. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
10. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
11. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Wang Y; Zhao L; Huang Q; Peng Y
J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
[No Abstract] [Full Text] [Related]
12. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
Tziomalos K; Bouziana SD; Spanou M; Kostaki S; Papadopoulou M; Giampatzis V; Dourliou V; Kostourou DT; Savopoulos C; Hatzitolios AI
Diab Vasc Dis Res; 2015 Nov; 12(6):463-6. PubMed ID: 26297528
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
15. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
Nadeau DA
Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
[TBL] [Abstract][Full Text] [Related]
16. [Management of Type 2 Diabetes: a Practical Approach].
Donath M
Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
19. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
20. Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome.
Tsukamoto K; Takemoto M; Kubota Y; Taniguchi T; Motegi SI; Taniguchi A; Nakagami H; Maezawa Y; Koshizaka M; Kato H; Mori S; Kuzuya M; Yokote K
Geriatr Gerontol Int; 2021 Feb; 21(2):133-138. PubMed ID: 33258561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
